On May 7, the Clinicaltrials website showed,AstraZenecaSubsidiaryFusion PharmaceuticalsDeveloped RadiopharmaceuticalsFPI-2265(225Ac-PSMA-I&T) Initiates Phase II/III Clinical Trials. This drug is the first radiopharmaceutical in AstraZeneca's pipeline to enter the late-stage development phase.This study is a randomized, multi-center, open-label clinical trial designed to evaluate FPI-2265 in patients who have received177Lu-PSMA-617Safety, Tolerability, and Antitumor Activity of FPI-2265 in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with 177Lu-PSMA or Other Radiotherapies. Enrolled patients will be divided into three cohorts receiving FPI-2265 treatment at doses of 50kBq/kg every 4 weeks, 75kBq/kg every 6 weeks, and 100kBq/kg every 8 weeks, respectively. The primary endpoints of the study are the proportion and duration of patients achieving a PSA50 response (at least a 50% reduction in PSA levels) and safety parameters.AstraZeneca has four radiopharmaceuticals in its pipeline, including FPI-2265 and FPI-1434.FPI-2068AndFPI-2059, except for FPI-2265, the other three are still in the early stages. In fact, these four radiopharmaceuticals all come fromFusion Pharmaceuticals. In March this year, AstraZeneca acquired the company for $2.4 billion, obtaining all of its assets.Copyright © 2024 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article.For reprint, please leave a message to the WeChat Official Account backend or send a message, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.↑Long press to scan the code, fill in the form to register↑
